Kevin Kunzmann

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.

Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.

The FDA approved the first 2 therapies to treat molluscum contagiosum in the last year. Silver explains how it's provided more than just treatment options.

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

Marinkovich discusses how the investigative cell-based graft therapy may serve a key role in the emerging DEB treatment paradigm.

Lio shares 3 aspects of pain management that dermatologists can consider to improve the experience of procedures for patients.

Joyce Teng, MD, PhD, reviews a pair of recently approved agents for DEB—as well as a cell therapy awaiting FDA decision this year.

Gene and cell therapies are reaching patients with the severe forms of epidermolysis bullosa. An expert explains their differing benefits and strengths.

Patients with both psoriasis and psoriatic arthritis may be more likely to be tired based on symptom severity.

The prominent clinical investigator joins to discuss adjuvant and neoadjuvant care research, as well as the application of biomarkers in personalized care.

In recognition of 60 years since the historic contribution to modern understanding of the harmful effects of cigarette smoking, Albert Rizzo, MD, meets with the preventive cardiology expert to discuss the myriad of cascading effects delivered by the 1964 report.

The first Lungcast of 2024 touches on one of the most pressing issues in medicine: burnout, with an organizational expert.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

A systematic review combined with a pair of case studies suggest men who discontinue the front-line treatment for conditions like polycythaemia vera may improve their fertility.

A new analysis suggests up to 3 in 10 patients who have an abnormal CT scan experience complications in follow-up procedures.

Analysis shows that biosimilar uptake was up to 2-fold greater in Medicare Advantage coverage than traditional Medicare.

A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.

Data from a nationally representative survey show that, despite most US adults agree the COVID-19 and flu vaccines are safe and effective, there is discrepancy in why some may not want one or the other.

Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.